Vadiee A R, Gillis T P, Shannon E J
Laboratory Research Branch, Gillis W. Long Hansen's Disease Center, Carville, LA 70721.
Clin Exp Immunol. 1990 Mar;79(3):397-402. doi: 10.1111/j.1365-2249.1990.tb08102.x.
A competitive antibody-binding assay (CABA) was developed to detect antibodies in infected armadillos and leprosy patients which compete with an M. leprae-specific 125I monoclonal antibody IIIE9 for the species-specific M. leprae-IIIE9 epitope on the 65-kD protein. The results suggest armadillos and leprosy patients produce antibodies that inhibit the binding of 125I-IIIE9 monoclonal antibody to the IIIE9 epitope on crude, native 65-kD protein preparations. When purified, recombinant 65-kD protein was substituted for crude antigen, there was no evidence in the CABA of antibody to the IIIE9 epitope. False-positive results, possibly induced by steric hindrance, are likely to be associated with CABA which incorporate crude cell wall extracts as solid-phase antigen.
开发了一种竞争性抗体结合试验(CABA),用于检测感染犰狳和麻风病患者体内与麻风分枝杆菌特异性125I单克隆抗体IIIE9竞争65-kD蛋白上种特异性麻风分枝杆菌-IIIE9表位的抗体。结果表明,犰狳和麻风病患者产生的抗体可抑制125I-IIIE9单克隆抗体与粗制天然65-kD蛋白制剂上的IIIE9表位结合。当用纯化的重组65-kD蛋白替代粗抗原时,在CABA中没有证据表明存在针对IIIE9表位的抗体。可能由空间位阻引起的假阳性结果,可能与将粗细胞壁提取物用作固相抗原的CABA有关。